• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cantargia

2.15 SEK

+0.56 %

1,288 following

CANTA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.56 %
-29.31 %
-48.54 %
-48.72 %
-47.59 %
+70.59 %
-50.98 %
-89.75 %
-69.63 %

Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.

Read more
Market cap
605.05M SEK
Turnover
965.34K SEK
Revenue
316.7M
EBIT %
48.66 %
P/E
3.64
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19/8
2026

Interim report Q2'26

25/11
2026

Interim report Q3'26

24/2
2027

Annual report '26

Press release2026-06-26 07:30

Cantargia tillkännager publicering av data som stöder IL1RAP som terapeutisk måltavla och prediktiv biomarkör vid PDAC

Cantargia
Press release2026-06-26 07:30

Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC

Cantargia
Regulatory press release2026-06-23 20:30

Cantargia offentliggör utfall i företrädesemission samt beslutar om en riktad emission av teckningsoptioner till Fenja Capital

Cantargia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-06-23 20:30

Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital

Cantargia
Press release2026-06-11 07:30

Cantargia och H.C. Wainwright arrangerar KOL Call om potentialen för nadunolimab i bukspottkörtelcancer

Cantargia
Press release2026-06-11 07:30

Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC

Cantargia
Press release2026-06-10 07:30

Cantargia startar ny prövarinitierad immunpreventionsstudie hos rökare med hög risk för lungcancer

Cantargia
Press release2026-06-10 07:30

Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study

Cantargia
Regulatory press release2026-06-05 08:15

Cantargia offentliggör informationsdokument avseende företrädesemission av aktier

Cantargia
Regulatory press release2026-06-05 08:15

Cantargia publishes Information Document regarding Rights Issue of Shares

Cantargia
Cantargia AB, Press Conference
Webcast2026-06-01 16:00

Cantargia AB, Press Conference

Cantargia
Press release2026-05-28 21:20

Cantargia AB bjuder in till webcast med anledning av företrädesemission, låneavtal och strategiska prioriteringar

Cantargia
Press release2026-05-28 21:20

Cantargia AB to Host Webcast covering Rights Issue, Loan Agreement, and Strategic Priorities

Cantargia
Regulatory press release2026-05-28 21:15

Cantargia AB genomför en företrädesemission om 124 MSEK samt ingår låneavtal om upp till 75 MSEK

Cantargia
Regulatory press release2026-05-28 21:15

Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million

Cantargia
Regulatory press release2026-05-21 16:00

Kommuniké från årsstämma i Cantargia AB (publ)

Cantargia
Regulatory press release2026-05-21 16:00

Bulletin from the Annual General Meeting in Cantargia AB (publ)

Cantargia
Press release2026-05-21 11:57

Redeye: Cantargia (Q1 Review): Shift Towards RAS Combination Strategy

Cantargia
Cantargia, Audiocast, Q1'26
Webcast2026-05-19 15:00

Cantargia, Audiocast, Q1'26

Cantargia
Regulatory press release2026-05-19 07:00

Cantargia publicerar delårsrapport för första kvartalet 2026

Cantargia